LY3009104: Phase IIb started

Eli Lilly began a double-blind, placebo-controlled, U.S. Phase IIb trial in 270 patients with active RA to evaluate once-daily 2, 4 and 8 mg LY3009104 for 24 weeks, and once-daily 1 mg LY3009104 for 1...